WO2001016359A3 - Screen for axon viability - Google Patents

Screen for axon viability Download PDF

Info

Publication number
WO2001016359A3
WO2001016359A3 PCT/GB2000/003360 GB0003360W WO0116359A3 WO 2001016359 A3 WO2001016359 A3 WO 2001016359A3 GB 0003360 W GB0003360 W GB 0003360W WO 0116359 A3 WO0116359 A3 WO 0116359A3
Authority
WO
WIPO (PCT)
Prior art keywords
axon
viability
screen
determining
sgc
Prior art date
Application number
PCT/GB2000/003360
Other languages
French (fr)
Other versions
WO2001016359A2 (en
Inventor
Giti Garthwaite
John Garthwaite
Original Assignee
Univ London
Giti Garthwaite
John Garthwaite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London, Giti Garthwaite, John Garthwaite filed Critical Univ London
Priority to AU68575/00A priority Critical patent/AU6857500A/en
Priority to GB0207441A priority patent/GB2370636A/en
Priority to EP00956708A priority patent/EP1220945A2/en
Publication of WO2001016359A2 publication Critical patent/WO2001016359A2/en
Publication of WO2001016359A3 publication Critical patent/WO2001016359A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

A method for determining the viability of an axon comprises: (i) contacting the axon with a substance that is capable of stimulating soluble guanylate cyclase (sGC); (ii) determining whether sGC is stimulated in the axon; and (iii) determining thereby whether the axon is viable.
PCT/GB2000/003360 1999-08-31 2000-08-31 Screen for axon viability WO2001016359A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU68575/00A AU6857500A (en) 1999-08-31 2000-08-31 Screen for axon viability
GB0207441A GB2370636A (en) 1999-08-31 2000-08-31 Screen for axon viability
EP00956708A EP1220945A2 (en) 1999-08-31 2000-08-31 Screen for axon viability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9920566.8 1999-08-31
GBGB9920566.8A GB9920566D0 (en) 1999-08-31 1999-08-31 Screen for axon viability

Publications (2)

Publication Number Publication Date
WO2001016359A2 WO2001016359A2 (en) 2001-03-08
WO2001016359A3 true WO2001016359A3 (en) 2002-05-10

Family

ID=10860090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003360 WO2001016359A2 (en) 1999-08-31 2000-08-31 Screen for axon viability

Country Status (4)

Country Link
EP (1) EP1220945A2 (en)
AU (1) AU6857500A (en)
GB (2) GB9920566D0 (en)
WO (1) WO2001016359A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
US7049334B2 (en) * 2001-09-14 2006-05-23 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
JP2005089457A (en) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd Pharmaceutical composition for promoting bone growth or inhibiting bone resorption
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CECIL KIM M ET AL: "Proton magnetic resonance spectroscopy for detection of axonal injury in the splenium of the corpus callosum of brain-injured patients.", JOURNAL OF NEUROSURGERY, vol. 88, no. 5, May 1998 (1998-05-01), pages 795 - 801, XP000990904, ISSN: 0022-3085 *
GARTHWAITE G ET AL: "Monitoring rat optic nerve axon viability using nitric oxide-stimulated cGMP accumulation: Application to the mechanism of ischaemic damage.", SOCIETY FOR NEUROSCIENCE ABSTRACTS., vol. 25, no. 1-2, 1999, 29th Annual Meeting of the Society for Neuroscience.;Miami Beach, Florida, USA; October 23-28, 1999, pages 1841, XP000990791, ISSN: 0190-5295 *
GARTHWAITE GITI ET AL: "Nitric oxide stimulates cGMP formation in rat optic nerve axons, providing a specific marker of axon viability.", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 11, no. 12, December 1999 (1999-12-01), pages 4367 - 4372, XP000990808, ISSN: 0953-816X *
MELDRUM B S ET AL: "Reduction of glutamate release and protection against ischemic brain damage by BW 1003C87.", BRAIN RESEARCH, vol. 593, no. 1, 1992, pages 1 - 6, XP000993068, ISSN: 0006-8993 *
SANGER J R ET AL: "HISTOCHEMICAL STAINING OF NERVE ENDINGS AS AN AID TO FREE MUSCLE TRANSPLANTATION", MICROSURGERY, vol. 12, no. 5, 1991, pages 361 - 366, XP000990903, ISSN: 0738-1085 *
XIE X M ET AL: "State-dependent inhibition of Na+ currents by the neuroprotective agent 619C89 in rat hippocampal neurons and in a mammalian cell line expressing rat brain type IIA Na+ channels.", NEUROSCIENCE, vol. 73, no. 4, 1996, pages 951 - 962, XP000993069, ISSN: 0306-4522 *
XIE XINMIN ET AL: "Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones.", PFLUEGERS ARCHIV EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 430, no. 3, 1995, pages 437 - 446, XP000993077, ISSN: 0031-6768 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Also Published As

Publication number Publication date
WO2001016359A2 (en) 2001-03-08
GB0207441D0 (en) 2002-05-08
EP1220945A2 (en) 2002-07-10
GB2370636A (en) 2002-07-03
GB9920566D0 (en) 1999-11-03
AU6857500A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
WO2004025434A3 (en) A method and apparatus for providing an instant win program
EP1432209A3 (en) Method and architecture to provide client session failover
EP0935415A4 (en) Methods for delivering compounds into a cell
WO2003102722A3 (en) Collaborative business plug-in framework
AU6375900A (en) Apparatus and methods for collaboratively searching knowledge databases
WO1997027380A3 (en) Method for forming a window in a tubular and apparatus for use in said method
GB2344126A (en) Releasable connector assembly for a perforating gun
WO2001092903A3 (en) Method and apparatus for maximizing test coverage
AU1602400A (en) Method and apparatus for executing electronic commercial transactions with minors
AU7478394A (en) Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
AU8626198A (en) Apparatus, system and method for the detection of an analyte in air
EP0855823A3 (en) Display method, display apparatus and communication method
WO1999013420A3 (en) Methods and apparatus for configuring schematic diagrams
EP1085470A3 (en) Method of creating a dynamic image, storage medium and program executing apparatus
WO2004010263A3 (en) Method and system for automating business processes
AU2001290649A1 (en) Method and apparatus for increasing the efficiency of transactions and connection sharing in an enterprise environment
WO2001016359A3 (en) Screen for axon viability
AU3527395A (en) Assay method
AU7043594A (en) A polychlorinated biphenyls (pcb) immunoassay method, its components and a kit for use in performing the same
AU2001294832A1 (en) Automated immunoassay analyzer and method of using the same
AU5230600A (en) Navigation apparatus and method
AU2707597A (en) Method of assay
AU4274289A (en) Method for implanting an object, and pistol
AU2003295060A1 (en) Loading of an application that is to be deployed in a terminal and a chip card
WO1998019039A3 (en) Apparatus and method for running tubulars

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: GB

Ref document number: 200207441

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000956708

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10069819

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000956708

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000956708

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP